# US 2021/0332028 A1 · Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332028 A1
- Document ID: US20210332028A1
- Status: Published application
- Kind: A1
- Application number: 17/273,774
- Filed: 2019-09-05
- Published: 2021-10-28
- Earliest claimed: 2018-09-06
- Assignees: Orion Corporation
- Applicants: Orion Corporation
- Inventors: David JONAITIS; Oskari KARJALAINEN
- Web page: https://patentgrep.com/patent/US20210332028A1

## CPC

- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- A61P 35/00: Antineoplastic agents
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to novel hydrochloride salt forms of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide (I). Compound (I) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.

## Claims

### Claim 1

A compound which is a hydrochloride salt of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)-cyclopropanesulfonamide (I).

### Claim 2 (depends on 1)

The compound according to claim 1, wherein the compound is in crystalline form.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein the compound is in crystalline form 1 and is characterized by a X-ray powder diffraction pattern comprising peaks at about 4.6, 9.6, 18.7, 19.2, 23.5, 25.0 and 26.9 degrees 2-theta.

### Claim 4 (depends on 2)

The compound according to claim 2, wherein the compound is in crystalline form 3 and is characterized by a X-ray powder diffraction pattern comprising peaks at about 7.2, 9.2, 11.6, 16.1, 18.5, 25.9 and 27.9 degrees 2-theta.

### Claim 5 (depends on 2)

The compound according to claim 2, wherein the compound is in crystalline form 5 and is characterized by a X-ray powder diffraction pattern comprising peaks at about 8.3, 9.5, 18.5, 19.8, 21.1, 23.9, 25.1 and 27.4 degrees 2-theta.

### Claim 6 (depends on 2)

The compound according to claim 2, wherein the compound is in crystalline form 8 and is characterized by a X-ray powder diffraction pattern comprising peaks at about 4.7, 14.2, 16.1, 18.0, 21.2, 23.5 and 26.5 degrees 2-theta.

### Claim 7 (depends on 6)

The compound according to claim 6, wherein the crystalline form is a monohydrate.

### Claim 8 (depends on 3)

A method of preparing a compound according to claim 3, comprising contacting the hydrochloride salt of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide with a mixture of aqueous hydrochloric acid and acetone, and isolating the crystalline product.

### Claim 9 (depends on 4)

A method of preparing a compound according to claim 4, comprising contacting the hydrochloride salt of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide with a mixture of aqueous hydrochloric acid and ethanol, and isolating the crystalline product.

### Claim 10 (depends on 5)

A method of preparing a compound according to claim 5, comprising grinding any crystalline form of the hydrochloride salt of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide in the presence of water, and isolating the crystalline product.

### Claim 11 (depends on 6)

A method of preparing a compound according to claim 6, comprising
(i) dissolving the hydrochloride salt of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide in a mixture of water and 2-propanol in the presence of hydrochloric acid and formic acid at elevated temperature,
(ii) cooling the mixture, and
(iii) isolating the crystalline product.

### Claim 12 (depends on 1)

A pharmaceutical dosage form comprising a compound according to claim 1 and an excipient.

### Claim 13 (depends on 1)

A method of treatment of treating cancer characterized by abnormal FGFR signalling, comprising administering a therapeutically effective amount of the compound according to claim 1 to a subject in need thereof.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the cancer is multiple myeloma, gastric cancer, endometrial cancer, prostate cancer, breast cancer, cholangiocarcinoma, or uroepithelial carcinoma.

### Claim 15 (depends on 7)

A method of preparing a compound according to claim 7, comprising:
(i) dissolving the hydrochloride salt of N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide in a mixture of water and 2-propanol in the presence of hydrochloric acid and formic acid at elevated temperature,
(ii) cooling the mixture, and
(iii) isolating the crystalline product.
